| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| Other Sizes |
| Targets |
TLR9
ODN 2395 sodium targets Toll‑like receptor 9 (TLR9), an endosomal pattern recognition receptor (PRR) that recognizes unmethylated CpG dinucleotides present in bacterial and viral DNA. TLR9 is expressed in B cells and plasmacytoid dendritic cells (pDCs). Upon binding to TLR9, ODN 2395 triggers the MyD88‑dependent signaling pathway, leading to activation of NF‑kappaB and IRF7. This results in the production of pro‑inflammatory cytokines (IL‑6, TNF‑alpha) and type I interferons (IFN‑alpha, IFN‑beta). ODN 2395 is a class C CpG ODN, which has properties of both class A (inducing high IFN‑alpha from pDCs) and class B (inducing strong B cell activation) CpG ODNs. |
|---|---|
| ln Vitro |
ODN 2395 sodium is a class C CpG ODN and a TLR9 agonist. It activates both B cells and plasmacytoid dendritic cells (pDCs), leading to the production of a broad range of cytokines, including type I interferons (IFN‑alpha) and IL‑6. In vitro, ODN 2395 (1-10 uM) induces the secretion of IFN‑alpha from human pDCs and promotes B cell proliferation and differentiation. It is also a potent inducer of cytokine/chemokine expression when used in combination with other immune stimulators. FITC‑labeled ODN 2395 is used to evaluate CpG ODN cellular uptake and localization by confocal microscopy or flow cytometry.
|
| ln Vivo |
ODN 2395 sodium has been studied in vivo for its immunostimulatory and adjuvant effects. In mice, administration of ODN 2395 (50-200 ug/mouse, IP or SC) induces the production of IFN‑alpha, IL‑6, and TNF‑alpha, and promotes Th1‑biased immune responses. In a Leishmania donovani infection model, CpG ODN 2395 enhanced immune responses and parasite clearance in obese and undernourished mice. ODN 2395 also promotes the immune response against Leishmania parasites in obesity and undernutrition mouse models, suggesting potential as a therapeutic agent.
|
| Enzyme Assay |
The binding of ODN 2395 to TLR9 is measured by cell‑free assays using purified recombinant human or mouse TLR9 protein. A fluorescence polarization (FP) or time‑resolved fluorescence resonance energy transfer (TR‑FRET) assay is used. A labeled CpG ODN (e.g., FITC‑labeled ODN 2395 or a fluorescent probe) is used as a tracer. Unlabeled ODN 2395 is added at graded concentrations (0.1-10,000 nM) to compete for binding. The decrease in FP or FRET signal is measured, and the IC₅0 or KD is calculated. No specific KD values are reported. Purity is ≥98% (HPLC).
|
| Cell Assay |
For cellular assays, human PBMCs, isolated B cells, or TLR9‑expressing cell lines (e.g., HEK‑Blue hTLR9 cells) are seeded in 96‑well plates (1-5 × 10⁵ cells/well). ODN 2395 is added at concentrations of 0.01-10 uM. After 6-48 h, the production of cytokines (IFN‑alpha, IL‑6, TNF‑alpha, IP‑10) in the supernatant is measured by ELISA. B cell proliferation is measured by [3H]‑thymidine incorporation or CFSE dilution. Activation of pDCs is assessed by flow cytometry for CD86, CD40, and HLA‑DR expression. FITC‑labeled ODN 2395 is used to measure cellular uptake: cells are incubated with labeled ODN (1-10 uM) for 1-24 h, and fluorescence is measured by flow cytometry or confocal microscopy.
|
| Animal Protocol |
For in vivo evaluation of immunostimulatory activity, 6‑8‑week‑old female BALB/c or C57BL/6 mice are used. ODN 2395 sodium is administered intraperitoneally (IP) or subcutaneously (SC) at doses of 50-200 ug/mouse, either alone or co‑administered with an antigen (e.g., OVA). Blood is collected at 2, 6, 12, and 24 h post‑injection for measurement of serum cytokines (IFN‑alpha, IL‑6, TNF‑alpha) by ELISA. Spleens are harvested for analysis of immune cell activation (e.g., CD86+ on DCs, CD69+ on B cells) by flow cytometry. In vaccine studies, mice are immunized on days 0, 14, and 28, and antigen‑specific antibody titers (IgG, IgG1, IgG2a) are measured by ELISA. For infection models (e.g., Leishmania donovani), mice are infected, then treated with ODN 2395 (50-100 ug/mouse, IP, 3-5 doses), and parasite burden is assessed.
|
| ADME/Pharmacokinetics |
ODN 2395 sodium is a synthetic oligodeoxynucleotide (sequence: 5‘‑tcgtcgttttcggcgc:gcgccg‑3‘, MW approx. 7000 Da). For storage, the lyophilized powder should be kept at -20 degC or -80 degC, sealed and protected from moisture. For in vitro use, stock solutions in sterile water or PBS (1-10 mg/mL) can be prepared and stored at -20 degC or -80 degC for up to 1 year. Avoid repeated freeze‑thaw cycles. For in vivo use, it is formulated in sterile PBS. No detailed PK parameters are reported.
|
| Toxicity/Toxicokinetics |
No specific toxicity data for ODN 2395 sodium are reported. As a potent immunostimulatory agent, its toxicity is associated with the risk of inducing uncontrolled systemic inflammation (cytokine storm) at high doses. In preclinical studies, doses up to 200 ug/mouse in C57BL/6 mice are generally tolerated without severe adverse effects. Standard laboratory safety precautions for handling nucleic acids should be followed. Not for human use.
|
| References | |
| Additional Infomation |
ODN 2395 sodium is a research‑grade class C CpG ODN. CpG ODNs are classified into three types (A, B, C) based on their structure and activity. Class A CpG ODNs (e.g., ODN 2216) strongly activate pDCs to produce IFN‑alpha but are weak B cell activators. Class B CpG ODNs (e.g., ODN 1826, ODN 1668) strongly activate B cells but produce little IFN‑alpha. Class C CpG ODNs (e.g., ODN 2395) combine the properties of both classes, inducing both strong IFN‑alpha production from pDCs and B cell activation. ODN 2395 has been studied as a vaccine adjuvant and for the treatment of infectious diseases and cancer. The sodium salt form is used to improve solubility and stability. The compound is for research use only and has not received regulatory approval.
|
| Molecular Weight |
7519.00
|
|---|---|
| Appearance |
Solid powder
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.1330 mL | 0.6650 mL | 1.3300 mL | |
| 5 mM | 0.0266 mL | 0.1330 mL | 0.2660 mL | |
| 10 mM | 0.0133 mL | 0.0665 mL | 0.1330 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
